©2022 Stanford Medicine
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Trial ID: NCT02383212
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Seema Nagpal, MD
Clinical Professor, Neurology & Neurological Sciences Clinical Professor (By courtesy), Neurosurgery
Reena Thomas, MD PhD
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Scott G. Soltys, MD
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Key Inclusion Criteria:
1. Histologically or cytologically confirmed diagnosis of malignancy with demonstrated
progression of a solid tumor (non-lymphoma) with no alternative standard-of-care
therapeutic option (certain exceptions may apply).
2. At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 criteria for response assessment (certain exceptions may apply)
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Key Exclusion Criteria:
1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that
required treatment with systemic immunosuppressive treatments, which may suggest risk
for immune-related adverse events (irAEs). The following are not exclusionary:
vitiligo, childhood asthma that has resolved, residual hypothyroidism that required
only hormone replacement or psoriasis that does not require systemic treatment.
2. Prior treatment with an agent that blocks the programmed death-1/ programmed
death-ligand 1 (PD-1/PD-L1 pathway) (certain exceptions may apply)
3. Prior treatment with other immune modulating agents within fewer than 4 weeks prior to
the first dose of cemiplimab. Examples of immune modulating agents include blockers of
CTLA-4, 4-1BB (CD137), OX-40, therapeutic vaccines, or cytokine treatments.
4. Untreated brain metastasis(es) that may be considered active. Patients with previously
treated brain metastases may participate provided they are stable (i.e., without
evidence of progression by imaging for at least 6 weeks prior to the first dose of
study treatment, and any neurologic symptoms have returned to baseline), and there is
no evidence of new or enlarging brain metastases, and the patient does not require any
systemic corticosteroids for management of brain metastases within 4 weeks prior to
the first dose of cemiplimab (certain exceptions may apply).
5. Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within
4 weeks prior to the first dose of cemiplimab
The information provided above is not intended to contain all considerations relevant to
potential participation in a clinical trial, therefore not all inclusion/ exclusion
criteria are listed.
radiation: Hypofractionated radiotherapy
School of Medicine
300 Pasteur Drive
Stanford, CA 94305